Competitive & Field Strategy
Strategy for markets where someone is shooting back.
The Problem We Solve
A clear-eyed read of the competitive board, and a field strategy that concentrates force where it changes outcomes.
You call us when a competitor launch or biosimilar entry is on the horizon. When field teams are busy but market share is not moving. When a board or portfolio decision needs a war-game before it's made. Or when your targeting logic predates the market you're now actually in.
Deliverables:
Defence and counter-launch strategy
Competitive scenario map and war-game
Field priority and segmentation review
Resource-concentration recommendations
How it works
Step 1
Board
The competitive landscape as it is, not as the last brand plan described it: players, timelines, likely moves.
Step 2
Scenarios
The two or three futures that matter, war-gamed with your team in the room.
Step 3
Response
The defence or counter-launch strategy, with its triggers: what you do, and what has to happen first.
Step 4
Concentration
Field priorities and resources refocused where they change outcomes — and withdrawn from where they don't.
You call us when the data is strong but the value story changes depending on who tells it. When partnering or fundraising discussions are coming and the commercial narrative lags the science. When an established standard of care makes differentiation harder than the clinical profile suggests. Or when a brand plan exists on paper but does not drive choices in the field.
Behind this practice: go-to-market leadership for a subcutaneous device and a rare-disease indication within a franchise that grew from $1B to $4.5B — and launch-team leadership for new indications and formulations on one of the world's largest biologics.
